Bioderma (France)

Sensitive skin syndrome (SSS) affects individuals from all ethnic groups. However, studies across different populations remain limited, despite recognised differences between populations. Thus, we examined SSS in Thai and Polish subjects, assessing the tolerance and efficacy of a dermo-cosmetic product in both populations. Thai participants were involved in a 28-day open-label study, while Polish subjects took part in a 56-day double-blind, randomised study comparing the product with a control cream. Clinical and functional signs were evaluated, alongside quality of life (QoL) using the Burden of Sensitive Skin (BoSS) questionnaire. The product was well tolerated in both groups over time, leading to significant improvements in all clinical and functional signs (p < 0.05 to p < 0.001) and enhancing QoL (p < 0.005 in Thailand; p < 0.001 in Poland). At baseline, Polish subjects exhibited greater redness and higher BoSS scores to questions relating to visual signs (p < 0.001). Conversely, Thai participants reported more pronounced tingling, pain and itching, along with higher BoSS scores relating to sensory symptoms (p < 0.001). The study highlights differences existing in the perception of SSS symptoms between a Thai and Polish population and demonstrates that the dermo-cosmetic cream effectively alleviates SSS symptoms and improves QoL in both ethnic groups.

Vitamin C or L-ascorbic acid (AA), its most biologically active form, is the most abundant antioxidant in healthy skin.Vitamin C is well-known for its anti-aging skin effects, like the inhibition of skin damage by free radicals, stimulation of collagen biosynthesis, inhibition of melanogenesis, and improvement of various inflammatory skin disorders. 1Thus, vitamin C is widely used in skin care products.However, vitamin C is highly unstable in aqueous solution, in the presence of oxygen and metal ions.Its oxidation is associated with a yellowish coloration of the formulation and loss of biochemical properties.AA stability in cosmetics remains a challenge despite several strategies, like the reduction of water content, the addition of antioxidants, the encapsulation in micro or nanoparticles, the use of more stable derivatives of vitamin C or multiple phase emulsions. 2o address this problem, an anhydrous formulation was developed, consisting of pure AA (10%) dissolved in two natural polyols compounds, propanediol and glycerin -a naturally occurring molecule of the skin.The anhydrous formulation stored in glass vials and white bottles remained colorless with a perfect stability of AA for 24 months at room temperature protected from light.Few clinical studies reported the efficacy of topical application of vitamin C alone or its derivatives on hyperpigmentation disorders caused by exposure to UV radiations (photoaging). 3,4AA decreases UVA-induced melanogenesis through its antioxidant properties 5 and may interfere with tyrosinase action, the main enzyme involved in melanin synthesis. 1 clinical study was conducted to assess the anti-spot/lightening effect and the acceptability of the new product.This clinical study complied with the Declaration of Helsinki, Good Clinical Practice Guidelines, and local laws and regulations.The European Directive 2001/20/EC and regulations issued by the Minister of Health (Order of the Minister of Health of May 2, 2012 regarding Good Clinical Practice, Dz.U.2012, item 491) was not applicable.Therefore, this study was considered as non-interventional and did not require the Ethics Committee Approval and the Competent Authority Authorization.All the subjects provided written informed consent prior to their participation in the study.Thirty-three healthy women, aged between 33 and 64 years, with sensitive skin, phototype I to III, and at least 1 pigmentary spot (lentigo > 3 mm) on the face were enrolled at the end of October 2020.Thirty-one subjects completed the study.They applied twice daily for 2 months 1 drop of the product on each cheek and on the forehead, then massaged until completely absorbed.Two zones were defined on the face, one with pigmentary spot and one with normal pigmentation, for color measurements using a Konica Minolta CM700-d spectrophotometer equipped with a 3 mm diameter head.The parameters L* (luminance) and b* (cutaneous melanin yellow color) were recorded on day 0 (baseline) (D0), then 28 (D28) and 56 days (D56) after product application.The Individual Typological Angle (ITA°) was calculated from the L* and b* parameters, ITA° being inversely related to pigmentation.The cutaneous acceptability of the product was assessed through an evaluation questionnaire on D56.L* and ITA° mean values increased on D28 and

Background: The quality of outcome assessment in acne studies has been either subjective/insufficient or time consuming through the ordinary lesion counting. Objective: To evaluate the application of multimodal clinical imaging (MCI), a combination of imaging technology and computation, in the assessment of acne lesions in a clinical study setting. Methods: A prospective, monocentric, single-group open study designed to evaluate the efficacy and tolerance of a cosmetic product (IP/SG) in subjects with mild-to-moderate facial acne by classical clinical counting (CCC) – change in the total/inflammatory/noninflammatory acne lesion number compared with baseline (D0) – Investigator Global Assessment (IGA) and self-reported outcomes. Concomitantly, MCI was administered. The study was performed for 12 weeks (D84) with a 4-week follow-up (D112). Results: Mean age of patients (n = 49) was 18.2 ± 3.7 years (range 13–25). The mean acne duration was 3.8 ± 2.8 years. The total number of lesions did not differ significantly between D0/D84 by both CCC and MCI. However, the Cardiff Acne Disability Index (CADI) and uncomfortable feeling improved at D28/D0, the perception of oily skin improved at D14/D0, and the perception of sticky skin improved from D28/D0 to D56/D0. Deterioration was detected between D84/D0 and D112/D0, namely after product discontinuation. Interestingly, a change in trend was recorded for acne lesions at D14/D0 by MCI but not by CCC. Conclusion: MCI, applied for the first time in a small clinical study setting, is at least as reliable as CCC and may allow for a sensitive longitudinal evaluation of single acne lesions and their response to products, especially in conditions where clinical evaluation reaches its limits.

AIM: Self-image is liable to deteriorate in a certain number of situations when a person has health problems and especially in the case of medical conditions needing a hospital stay. Socio-esthetics is a field that was founded in the 1960s. It is starting to catch on in hospitals when the patient needs comprehensive care.The objective of this study was to evaluate socio-esthetic activity that started in April 2013at Nantes University Hospital (Hôtel-Dieu site). METHODS: Between April 2013 and April 2015, a questionnaire was given to patients who used a socio-esthetician in order to evaluate the benefits of esthetic care and other services such as hair removal. RESULTS: Facial care and massageswere the services most often requested bypatients.This moment was experienced as a relaxing moment, followed by an improvement in skin comfort for 85% of patients. CONCLUSION: This socio-esthetic experience was felt to be very satisfying for 99% of patients who benefited from it.

Atopic dermatitis (AD) is an inflammatory and pruritic skin disorder. To assess the efficacy and tolerance of a new emollient (SBT complex) in subjects with moderate AD. Subjects received twice daily for 168 days (6 months) either SBT complex or emollient base adjunctively or alternately with topical corticosteroids or calcineurin inhibitors. Evolution of AD was assessed throughout the study using usual AD assessment criteria including SCORAD and PO-SCORAD. Quality of life was assessed at Day 0 and Day 168. At Day 168, a significant decrease with SBT complex was observed for the SCORAD and the PO-SCORAD scores (P < 0.05), the primary efficacy criteria. A total of 76% of SBT complex subjects did not relapse and time-to-relapse increased compared to the emollient base subjects. Intensity, dryness, and quality of life (P < 0.05) had improved in subjects using SBT complex. The product was well tolerated with less physical and functional signs in the SBT than in the emollient base group. The new emollient dermocosmetic SBT complex applied adjunctively or alternately with topical AD treatments significantly improved AD without any safety concerns. SBT complex may play an important role in the restoration of the natural skin barrier.